On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- COPD exacerbation
- Respiratory viruses and exacerbation
- Changes in bacterial load
- Exacerbation and bacterial strain change
- Lung microbiome
- Bacteria importance in exacerbation
- Factors that affect treatment
- Oral steroids at COPD exacerbation
- Sputum IL1-beta at bacterial exacerbation
- IP-10a ROC curve analysis
- Virus induce airway inflammation mechanism
- IFN-gamma mRNA and protein deficiency
- Experimental infection interferon production
- Exacerbation recovery
- Fatigue association with COPD exacerbation
- Exacerbation frequency and exercise capacity
- Pulmonary rehabilitation program
- Early pulmonary rehabilitation
- Reduction in exacerbation triggers
- Pollution and COPD exacerbation
- Significance of treatment delay and recovery time
- Symptom onset and early start of therapy
- Exacerbation clustering
- Importance of exacerbation
- Susceptibility to exacerbation
- Association of disease severity with exacerbations
- Factors associated with exacerbation frequency
- The NICE algorithm
- Poet study- salmeterol vs. tiotropium
- Indacaterol
- Rate of moderate and severe exacerbation
- Torch study: analysis by disease severity
- Uplift mild* COPD subgroup: exacerbations
- Inspire study
- Time to first exacerbation
- Roflumilast
- The effect of roflumilast on exacerbations
- Roflumilast significantly reduce exacerbation rate
- Rationale for macrolide use in COPD
- Macrolides - time to first exacerbation
- Symptom duration is responsive to therapy
- Macrolides - sputum markers
- Macrolides (azithromycin) study
- Macrolides study data analysis
- Long term antibiotics
- Bacterial load and airway inflammation
- Sub-group analysis
- Relation of comorbidity to COPD exacerbation
- Beta blockers treatment
- Non-pharmacological interventions
- Optimal care new perspective
Topics Covered
- Definition of exacerbations
- Breakdown of virus directed exacerbations
- Pollution and COPD
- Importance of exacerbations
- Eclipse study
- Poet study
- Torch study
- Inspire study
- Antibiotic use in COPD patients
- Non-pharmacological interventions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wedzicha, W. (2012, September 10). Mechanisms of COPD exacerbations and relation to exacerbation therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/PBRD8172.Export Citation (RIS)
Publication History
- Published on September 10, 2012
Financial Disclosures
- Prof. Wisia Wedzicha has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide